News & AnalysisInflammatix grabs $102m Series DInflammatix, a molecular diagnostics company, has secured $102 million in Series D financing.ByIris Dorbian16 March 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs